Where are we with the treatment of metastatic bladder cancer?

Expert Opinion on Investigational Drugs

Volumn 16, Issue 9, 2007, Pages 1311-1314

  Papatsoris, Athanasios G ^a,b   Kachrilas, Stefanos ^a   Gekas, Aristomenis ^a  

^a Department of Urology   (Greece)

^b NONE   (Greece)

Author keywords

Bladder cancer; Chemotherapy; Cisplatin; Gemcitabine; Metastasis; Survival; Taxanes

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ENDOSTATIN; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FUMAGILLOL CHLOROACETYLCARBAMATE; GEFITINIB; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; LAPATINIB; METHOTREXATE; PACLITAXEL; PEMETREXED; PLATINUM COMPLEX; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; VASCULOTROPIN ANTIBODY; VINBLASTINE; VINFLUNINE;

BLADDER CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER REGRESSION; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG EFFICACY; DRUG EXCRETION; DRUG MEGADOSE; EDITORIAL; GASTROINTESTINAL TOXICITY; HUMAN; METASTASIS; MONOTHERAPY; NEPHROTOXICITY; NEUROTOXICITY; PROGNOSIS; UNSPECIFIED SIDE EFFECT; ARTICLE; BLADDER TUMOR;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; URINARY BLADDER NEOPLASMS;

EID: 34548556363     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.9.1311     Document Type: Editorial

References (20)

1. JAKSE G, ALGABA F, FOSSA S, STENZL A, STERNBERG C: Guidelines on bladder cancer: muscle-invasive and metastatic. In: European Association of Urology Guidelines. Board EAU Guidelines Office, EAU, Arnhem, The Netherlands (2007):1-24.
2. PAPATSORIS AG, DELIVELIOTIS C, GIANNOPOULOS A, DIMOPOULOS C: Adjuvant intravesical mitoxantrone versus recombinant IFN-α after transurethral resection of superficial bladder cancer. A randomized prospective study. Urol. Int. (2004) 72(4):284-291.
3. LOGOTHETIS CJ, DEXEUS FH, FINN L et al.: A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. (1990) 8(6):1050-1055.
4. STERNBERG CN, DONAT SM, BELLMUNT J et al.: Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. Urology (2007) 69(1 Suppl.):62-79.
5. BAMIAS A, TILIAKOS I, KARALI MD, DIMOPOULOS MA. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann. Oncol. (2006) 17(4):553-561.
6. ROSENBERG JE, CARROLL PR, SMALL EJ: Update on chemotherapy for advanced bladder cancer. J. Urol. (2005) 174(1):14-20.
7. GARCIA JA, DREICER R: Systemic chemotherapy for advanced bladder cancer: update and controversies. J. Clin. Oncol. (2006) 24(35):5545-5551.
8. STERNBERG CN, DE MULDER PH, SCHORNAGEL JH et al.: Randomized Phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (WAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer Protocol no. 30924. J. Clin. Oncol. (2001) 19(10):2638-2646.
9. VON DER MAASE H, HANSEN SW, ROBERTS JT et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, Phase III study. J. Clin. Oncol. (2000) 18(17):3068-3077.
10. STERNBERG CN, CALABRÒ F, PIZZOCARO G, MARINI L, SCHNETZER S, SELLA A: Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer (2001) 92(12):2993-2998.
11. BELLMUNT J, GUILLEM V, PAZ-ARES L et al.: Phase I-II study of paditaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. Spanish Oncology Genitourinary Group. J. Clin. Oncol. (2000) 18(18):3247-3255.
12. HUSSAIN M, VAISHAMPAYAN U, DU W, REDMAN B, SMITH DC: Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. J. Clin. Oncol. (2001) 19(9):2527-2533.
13. BAJORIN DF, MCCAFFREY JA, HILTON S et al.: Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a Phase II trial. J. Clin. Oncol. (1998) 16(8):2722-2727.
14. POLLERA CF, NELLI F: Developing innovative strategies for advanced transitional cell carcinoma of the bladder. Erpert Rev. Anticancer Ther. (2006) 6(1):83-92.
15. BEEKMAN KW, BRADLEY D, HUSSAIN M: New molecular targets and novel agents in the treatment of advanced urothelial cancer. Semin. Oncol. (2007) 34(2):154-164.
16. PAZ-ARES L, BEZARES S, TABERNERO JM, CASTELLANOS D, CORTES-FUNES H: Review of a promising new agent - pemetrexed disodium. Cancer (2003) 97(Suppl. 8):2056-2063.
17. JIMENEZ RE, HUSSAIN M, BIANCO FJ: Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors. Clin. Cancer Res. (2001) 7(8):2440-2447.
18. INOUE K, CHIKAZAWA M, FUKATA S, YOSHIKAWA C, SHUIN T: Frequent administration of angiogenesis inhibitor TNP-470 (AGM-1470) at an optimal biological dose inhibits tumor growth and metastasis of metastatic human transitional cell carcinoma in the urinary bladder. Clin. Cancer Res.(2002) 8(7):2389-2398.
19. CALABRÒ F, STERNBERG CN: State-of-the-art management of metastatic disease at initial presentation or recurrence. World J. Urol. (2006) 24(5):543-556.
20. BELLMUNT J, ALBIOL S: Chemotherapy for metastatic or unresectable bladder cancer. Semin. Oncol. (2007) 34(2):135-144.